PWS
TBPH icon

Precision Wealth Strategies’s Theravance Biopharma TBPH Stock Holding History

Precision Wealth Strategies’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62,815
Closed -$1.02M – 189
2026
Q1 		$1.02M Buy
+62,815
New +$1.11M 0.34% 71

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Precision Wealth Strategies's TBPH Position: Q2 2026 in Review

Precision Wealth Strategies sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 62,815 shares — an estimated $1.02M sold.

Precision Wealth Strategies first reported a position in TBPH in Q1 2026 and held it in 1 quarter. The position peaked at $1.02M in Q1 2026. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Precision Wealth Strategies reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Precision Wealth Strategies sold 62,815 Theravance Biopharma shares in Q2 2026, an estimated $1.02M.
  • Precision Wealth Strategies first reported a position in Theravance Biopharma in Q1 2026 and held it in 1 quarter.
  • Precision Wealth Strategies's Theravance Biopharma position peaked at $1.02M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Precision Wealth Strategies's 13F filing for Q2 2026, filed 10 Aug 2026.